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Objectives The aim of this study was to investigate the possible effects of antiretroviral therapy (ART) in utero on cardiac
development and function in human immunodeficiency virus (HIV)–negative children.
Background ART reduces vertical HIV transmission. Long-term cardiotoxicity after in utero exposure to ART is unknown in
children but has occurred in young animals.
Methods Using a prospective multisite cohort study design, echocardiograms taken between birth and 24 months were
compared in 2 groups of HIV-negative infants of HIV-positive mothers: 136 infants exposed to ART (ART) and
216 unexposed infants (ART).
Results Mean left ventricular (LV) mass z-scores were consistently lower in ART girls than in ART girls: differences in
mean z-scores were 0.46 at birth (p  0.005), 1.02 at 6 months (p  0.001), 0.74 at 12 months (p 
0.001), and 0.79 at 24 months (p  0.001). Corresponding differences in z-scores for boys were smaller: 0.13
at 1 month (p  0.42), 0.44 at 6 months (p  0.01), 0.15 at 12 months (p  0.37), and 0.21 at 24
months (p  0.21). Septal wall thickness and LV dimension were smaller than expected in ART infants, but LV
contractility was consistently about 1 SD higher at all ages (p  0.001). In ART infants, LV fractional shorten-
ing was higher than in ART infants; girls showed a greater difference.
Conclusions Fetal exposure to ART is associated with reduced LV mass, LV dimension, and septal wall thickness z-scores and
increased LV fractional shortening and contractility up to age 2 years. These effects are more pronounced in
girls than in boys. Fetal ART exposure may impair myocardial growth while improving depressed LV
function. (J Am Coll Cardiol 2011;57:76–85) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.08.620(
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December 28, 2010/January 4, 2011:76–85 Cardiac Status of HIV- and ART-Exposed Infantsility that persists at 5 years of age, whereas HIV-positive
ewborns experience chronic and progressive abnormalities
n LV structure and function (6).
Mitochondrial abnormalities have been reported in ani-
als and children exposed to ART, with inconsistent results
7–12). Such abnormalities could cause cardiomyopathy in
xposed children, although the clinical implications of
itochondrial abnormalities in HIV-negative infants ex-
osed to ART are uncertain (7–12).
Nearly 10,000 ART-exposed and HIV-exposed but neg-
tive infants are born annually in the U.S. but are not
outinely followed for suspicion of heart disease (8–10,13).
To study the cardiac effects of perinatal exposure to ART,
e compared 2 cohorts of HIV-negative children born to
IV-positive mothers.
ethods
n the CHAART-1 (Cardiovascular Status of HAART
herapy in HIV-Exposed Infants and Children) cohort
tudy (14), 166 HIV-negative infants exposed to ART in
tero were prospectively identified between June 2003 and
anuary 2006 from the WITS (Women and Infants Trans-
ission Study) of 2,842 infants born to HIV-positive
omen (15). CHAART-1 participants came from 5 of the
WITS sites; 4 also participated in the P2C2 HIV (Pedi-
tric Pulmonary and Cardiac Complications of Vertically
ransmitted HIV Infection) study. CHAART-1 partici-
ants were enrolled in WITS and were age 2 years or less so
hat primary end points could be measured at age 2 years.
HAART-1–recruited children were followed until loss to
ollow-up, the child withdrew, December 2006, or which-
ver came first.
Maternal exclusion criteria for CHAART-1 children
ncluded diabetes, phenylketonuria, a Mendelian or chro-
osomal defect, a heart defect requiring medication or
urgery, or pregnancy exposures to chemotherapy, radiation,
r drugs associated with heart disease in offspring.
The P2C2 HIV study prospectively described cardiovas-
ular disorders in children born to HIV-positive mothers
nrolled between 1990 and 1994 at 6 centers (16). Of the
63 HIV-negative infants enrolled during gestation or
ithin 28 days after birth, 262 had no in utero or post-natal
RT exposure and were the non-ART-treated controls.
he P2C2 HIV study showed that independently of ART,
IV-negative children born to HIV-positive women have
bnormal LV structure and function, making them an
ssential control group when assessing the impact of ART
herapy in the CHAART-1 study (6).
CHAART-1 sites received institutional review board
pproval to collect serial echocardiograms. Written in-
ormed consent was obtained from parents or guardians.
Prospective data were collected from the CHAART-1
nd P2C2 HIV datasets. Cardiac function was evaluated
hrough serial echocardiograms starting at birth or the visit
losest to CHAART-1 enrollment and ending on Decem- Ier 31, 2006. Echocardiograms
ere scheduled at 6 intervals
rom 1 to 48 months of age. The
orresponding P2C2 HIV collec-
ion was scheduled at 14 intervals
rom birth to 54 months. In this
eport, we analyze echocardio-
raphic data for participants up
o age 2 years.
The P2C2 HIV echocardiographic acquisition protocol
as followed (2,14). Echocardiographic data were digitized
y the same independent, blinded cardiologist who had
easured the previous P2C2 HIV and Boston control
chocardiographic data (17).
tatistical methods. CHAART-1 compared 2 primary
chocardiographic end points at age 2 years with respect to
n utero ART exposure: LV mass and fractional shortening.
lpha was set at 0.025 to correct for multiple comparisons.
ll other analyses were carried out at the 0.05 alpha level
nd should be considered as suggestive findings in need of
uture confirmation.
General linear models were used to determine whether
RT independently predicted changes in these 2 measures
nd to identify any ART-covariate interactions. Serial
chocardiographic measurements from birth to 2 years were
nalyzed using generalized estimating equations (18). Twins
nd infants whose maternal ethnicity was other than African
merican, Caucasian, or Hispanic were excluded.
The echocardiographic measures were standardized to
-scored deviations using Boston infants and children as the
ormal reference population (2). Z-scores were used as an
djustment mechanism to correct echocardiographic mea-
urements for heart growth and development. Z-scores of
ero correspond to an average heart parameter measure-
ent, negative to below average, and positive to above
verage. Numeric values correspond to changes in standard
eviation units. The methodology is identical to the growth
harts versus age for height and weight in children that are
rovided by the Centers for Disease Control and Preven-
ion. As long as the comparison is made with populations
hat are not markedly different from the normal control
eference population with regard to factors such as body
ass index, level of habitual exercise (i.e., exclusion of elite
thletes), and blood pressure, no differences in z-scores are
nticipated.
Interaction terms of ART exposure with sex, ethnicity,
nd age that were significant at 0.05 were included in the
nal models. Alpha at 0.05 determined statistical signifi-
ance in all analyses, except for the primary end points (see
he preceding discussion), because these were hypothesis-
enerating analyses. The effect of ART exposure on primary
nd points was analyzed without adjustments and with
djustment for sex, ethnicity, significant maternal charac-
eristics, and significant sex-ART interaction.
All analyses were performed using SAS version 8.2 (SAS
Abbreviations
and Acronyms
ART  antiretroviral
therapy
HIV  human
immunodeficiency virus
LV  left ventricularnstitute Inc., Cary, North Carolina).
Do
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Cardiac Status of HIV- and ART-Exposed Infants December 28, 2010/January 4, 2011:76–85emographic Characteristics, Maternal CD4 and CD8 T-Lymphocyte Measurements, and Infant Blood Pressure Measurementsf 352 HIV-Negative Infants and Their HIV-Positive Mothers According to Perinatal Exposure to Antiretroviral TherapyTable 1 Demographic Charac stics, M ternal CD4 and CD8 T-Lymphocyt Me sureme s, an Infant Blood Pressur Measurementsof 352 HIV-Negative Infants and Their HIV-Positive Mothers According to Perinatal Exposure to Antiretroviral Therapy
Variable
CHAART-1 Infants
Exposed to Antiretroviral Therapy
(n  136)
P2C2 HIV Infants
Not Exposed to Antiretroviral Therapy
(n  216) p Value*
Characteristics of mothers during pregnancy
Ethnicity 0.20
Black 83 (61%) 120 (56%)
White 10 (7%) 29 (13%)
Hispanic 43 (32%) 67 (31%)
Age at delivery (yrs) 0.08
30 84 (62%) 153 (71%)
30 52 (38%) 63 (29%)
Tobacco use 0.003
Yes 30 (22%) 79 (37%)
No 106 (78%) 133 (62%)
Unknown 0 (0%) 4 (2%)
Alcohol use 0.72
Yes 32 (24%) 46 (21%)
No 104(76%) 164 (76%)
Unknown 0 (0%) 6 (3%)
Illicit drug use 0.002
Yes 21 (15%) 63 (29%)
No 115 (85%) 149 (69%)
Unknown 0 (0%) 4 (2%)
Vaginal bleeding 0.001
Yes 34 (25%) 6 (3%)
No 102 (75%) 209 (97%)
Unknown 0 (0%) 1 (1%)
Gestational diabetes 0.56
Yes 3 (2%) 7 (3%)
No 133 (98%) 207 (96%)
Unknown 0 (0%) 2 (1%)
Pre-eclampsia 0.26
Yes 1 (1%) 5 (2%)
No 135 (99%) 210 (97%)
Unknown 0 (0%) 1 (1%)
Cesarean section 0.001
Yes 55 (40%) 38 (18%)
No 81 (60%) 178 (82%)
Characteristics of infants
Sex 0.90
Male 74 (54%) 116 (54%)
Female 62 (46%) 100 (46%)
Premature birth (37 weeks) 0.24
Yes 15 (11%) 33 (15%)
No 121 (89%) 181 (85%)
Unknown 0 (0%) 2 (1%)
Birth weight (g) 0.09
2,500 12 (9%) 32 (15%)
2,500 124 (91%) 182 (84%)
Unknown 0 (0%) 2 (1%)
Maternal CD4 and CD8 T-lymphocyte measurements during pregnancy
CD4 count (cells/mm3) 532.2 (491.7 to 572.7) 586.2 (517.1 to 655.2) 0.18
CD4 (%) 30.7 (28.9 to 32.5) 30.3 (28.7 to 31.8) 0.73
CD8 count (cells/mm3) 796.1 (739.3 to 852.9) 904.4 (820.4 to 988.4) 0.04
CD8 (%) 45.7 (43.8 to 47.6) 48.0 (46.1 to 50.0) 0.09(Continued on next page)
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emographic and clinical characteristics. Data were col-
ected from 136 ART-exposed, HIV-negative infants from
he CHAART-1 centers and from 216 non-ART-exposed,
IV-negative infants from the P2C2 HIV study (Table 1)
19). Infant sex and maternal ethnicities were similar.
owever, the maternal CHAART-1 cohort used tobacco
22% vs. 37%) and illicit drugs (15% vs. 29%) less, and their
nfants had higher birth weights. CHAART-1 mothers
xperienced vaginal bleeding during pregnancy (25% vs. 3%)
nd cesarean-section delivery (40% vs. 18%) more fre-
uently. Immunologic studies were similar, except for a
igher mean CD8 T-lymphocyte count in the P2C2 HIV
others (p  0.04) (Table 1). In utero ART exposure for
he 136 CHAART-1 infants was 6 (4%) for mono-ART,
1 (8%) for combination ART (2 or more ART drugs,
ithout a non-nucleoside reverse transcriptase inhibitor or
rotease inhibitor), and 119 (88%) for highly active ART (3
r more ART drugs, including a non-nucleoside reverse
ranscriptase inhibitor or protease inhibitor).
Data included 234 serial echocardiograms from CHAART-1
nfants (mean 1.7 per child) and 516 serial echocardiograms from
2C2 HIV infants (mean 2.4 per child). Mean systolic and
iastolic blood pressure z-scores were higher in ART-exposed
ale infants compared with unexposed male infants (Table 1).
djustment variables for each analysis in a table are presented
n the footnote of that table.
rimary end point evaluations. The unadjusted LV mass
-score for all CHAART-1 infants at age 2 years was 0.53
D less than in the P2C2 HIV cohort (p 0.006). LV mass
nd ART remained associated after adjusting for sex,
ex-ART interaction (p  0.009), ethnicity, and maternal
aginal bleeding (p  0.01). Both the unadjusted and
ontinuedTable 1 Continued
Variable
CH
Exposed to
Infant blood pressure z-scores at the time of echocardiography†
Diastolic
Overall 0.43
Boys 0.50
Girls 0.35
Systolic
Overall 0.31
Boys 0.50
Girls 0.10
Echocardiography age groups†
Birth visit (0 to 2 months) 54
6-month visit (5 to 8 months) 50
1-yr visit (11 to 22 months) 64
2-yr visit (23 to 34 months) 66
ata are expressed as n (%) or as mean (95% confidence interval). *Chi-square analysis: observatio
f infants exposed to antiretroviral therapy and 516 measurements of unexposed infants.
CD  cluster of differentiation; CHAART-1  Cardiovascular Status of HAART Therapy in HIV-Exp
ardiac Complications of Vertically Transmitted HIV Infection.djusted LV mass z-scores were smaller in the CHAART-1 Aroup when pooling across sex; most of the difference was
mong girls, who showed a greater reduction (Table 2).
The unadjusted LV fractional shortening z-score for
HAART-1 infants was 0.45 SD greater than that of the
2C2 HIV infants (p  0.01) at age 2 years. For this
utcome, there was no sex-ART interaction. LV fractional
hortening and ART remained significantly associated after
djusting for sex and ethnicity. Both the unadjusted and
djusted LV fractional shortening z-scores were higher in
he CHAART-1 group, with girls showing a greater but
onsignificant difference (Table 2).
ongitudinal analyses of cardiac outcomes. LV fractional
hortening and LV mass end points were similar to the
utcomes at age 2 years, except that the sex-ART interac-
ion for LV fractional shortening was more prominent and
tatistically significant. The sex-ART differences for these 2
nd points were present by age 6 months and remained at
ge 2 years.
Adjusted LV end-systolic dimension z-scores were lowest
n the ART-exposed group, with the greatest differences in
irls (0.52 SD lower in the ART-exposed than the non-
RT-exposed girls). Adjusted LV end-diastolic dimension
-scores were lower in the ART-exposed girls at age 6
onths and age 2 years (0.44 SD and 0.51 SD, respec-
ively). LV contractility was 0.72 SD and 1.11 SD higher in
RT-exposed boys and girls, respectively. End-diastolic
eptal wall thickness was 0.82 SD and 1.42 SD lower in
RT-exposed boys and girls, respectively. For the cardiac
nd points without sex-by-ART interaction, results were
ombined across sexes (Table 3).
ther treatment interactions for cardiac end points.
ardiac outcomes had statistically significant sex-by-
reatment or time-by-treatment interactions (Figs. 1 and 2).
1 Infants
etroviral Therapy
136)
P2C2 HIV Infants
Not Exposed to Antiretroviral Therapy
(n  216) p Value*
to 0.59) 0.23 (0.14 to 0.33) 0.04
to 0.73) 0.22 (0.10 to 0.34) 0.04
to 0.57) 0.25 (0.10 to 0.39) 0.45
to 0.50) 0.005 (0.1 to 0.1) 0.006
to 0.78) 0.004 (0.15 to 0.14) 0.003
4 to 0.34) 0.02 (0.14 to 0.17) 0.56
) 173 (34%) —
) 96 (19%) —
) 155 (30%) —
) 92 (18%) —
unknown data were excluded from p value calculation. †Values are based on 234 measurements
fants and Children; HIV  human immunodeficiency virus; P2C2 HIV  Pediatric Pulmonary andAART-
Antir
(n 
(0.26
(0.26
(0.12
(0.12
(0.20
(0.1
(23%
(21%
(27%
(28%
ns withmong CHAART-1 boys, mean LV mass was higher at 1
Sb
*
b
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Cardiac Status of HIV- and ART-Exposed Infants December 28, 2010/January 4, 2011:76–85ex-Specific Cardiac Outcomes Among 352 HIV-Negative Infants Born to HIV-Positive Mothers,y Ex osure to Antiretroviral Therapy*Table 2 Sex-Specific C rdiac Outcomes Among 352 HIV-Negative Infants B rn to HIV-Positive Mothers,by Exposure to Antiretroviral Therapy*
Cardiac Measure Sex Study
Population Mean Adjusted Estimate
Birth 6 Months 1 Yr 2 Yrs Birth 6 Months 1 Yr 2 Yrs
LV mass z-scores†
Male CHAART-1 0.67 0.88 0.87 0.34 0.72§ 1.01§ 0.64§ 0.43§
P2C2 HIV 0.92 0.58 0.46 0.26 0.85§ 0.58§ 0.49§ 0.23‡
 0.25 0.30 0.41 0.08 0.13 0.44 0.15 0.21
p value 0.42 0.01 0.37 0.21
Female CHAART-1 1.14 1.63 0.89 0.99 1.17§ 1.46§ 1.09§ 0.88§
P2C2 HIV 0.67 0.43 0.37 0.08 0.71§ 0.44§ 0.35§ 0.09
 0.47 1.20 0.52 0.91 0.46 1.02 0.74 0.79
p value 0.005 0.001 0.001 0.001
LV fractional shortening z-scores†
Male CHAART-1 0.93 0.59 0.20 0.30 0.89§ 0.58§ 0.21 0.28
P2C2 HIV 2.12 0.24 0.30 0.04 2.12§ 0.36‡ 0.29‡ 0.05
 1.19 0.35 0.10 0.33 1.22 0.22 0.08 0.33
p value 0.001 0.36 0.69 0.12
Female CHAART-1 0.43 0.89 0.50 0.52 0.59§ 0.89§ 0.52§ 0.59§
P2C2 HIV 2.44 0.15 0.14 0.22 2.35§ 0.13 0.06 0.28
 2.01 0.74 0.36 0.74 1.76 0.76 0.46 0.87
p value 0.001 0.003 0.04 0.001
LV end-diastolic dimension z-scores†
Male CHAART-1 0.32 0.90 0.48 0.31 0.49§ 1.04§ 0.45§ 0.35§
P2C2 HIV 0.99 0.96 0.66 0.08 0.91§ 0.96§ 0.66§ 0.20‡
 0.67 0.06 0.19 0.23 0.42 0.08 0.20 0.15
p value 0.009 0.61 0.22 0.36
Female CHAART-1 0.85 1.46 0.74 0.63 0.79§ 1.34§ 0.75§ 0.64§
P2C2 HIV 0.79 0.84 0.58 0.41 0.86§ 0.90§ 0.60§ 0.14
 0.05 0.62 0.16 0.22 0.07 0.44 0.15 0.51
p value 0.66 0.006 0.34 0.003
LV end-systolic dimension z-scores
Male CHAART-1 0.39 1.20 0.61 0.44 0.57§ 1.25§ 0.78§ 0.35§
P2C2 HIV 0.58 1.12 0.82 0.12 0.53§ 1.21§ 0.74§ 0.31§
 0.19 0.08 0.22 0.33 0.04 0.04 0.04 0.04
p value 0.78 0.78 0.78 0.78
Female CHAART-1 1.01 1.75 0.95 0.80 0.91§ 1.59§ 1.12§ 0.69§
P2C2 HIV 0.30 0.96 0.69 0.30 0.39§ 1.07§ 0.60§ 0.17
 0.72 0.79 0.26 0.50 0.52 0.52 0.52 0.52
p value 0.001 0.001 0.001 0.001
LV contractility z-scores
Male CHAART-1 0.10 0.24 0.08 0.38 0.14 0.31‡ 0.09 0.39§
P2C2 HIV 0.51 0.55 0.90 0.18 0.58§ 0.41§ 0.81§ 0.33§
 0.61 0.79 0.98 0.56 0.72 0.72 0.72 0.72
p value 0.001 0.001 0.001 0.001
Female CHAART-1 0.26 0.38 0.11 0.33 0.15 0.33§ 0.07 0.41§
P2C2 HIV 1.11 0.67 1.09 0.77 0.95§ 0.78§ 1.17§ 0.70
 1.37 1.05 0.98 1.10 1.11 1.11 1.11 1.11
p value 0.001 0.001 0.001 0.001
End-diastolic septal wall thickness z-scores
Male CHAART-1 0.08 0.32 0.81 0.31 0.12 0.28‡ 0.41§ 0.55§
P2C2 HIV 0.95 0.70 0.48 0.03 0.94§ 0.54§ 0.41§ 0.27
 0.87 1.01 1.29 0.27 0.82 0.82 0.82 0.82
p value 0.001 0.001 0.001 0.001
Female CHAART-1 0.25 0.79 0.49 0.76 0.15 0.55§ 0.68§ 0.82§
P2C2 HIV 1.26 0.88 0.72 0.64 1.27§ 0.87§ 0.74§ 0.60§
 1.51 1.67 1.21 1.40 1.42 1.42 1.42 1.42
p value 0.001 0.001 0.001 0.001
Crudemeasurements and estimates from regression models are adjusted for age, sex, ethnicity, and interaction between sex and exposure to antiretroviral therapy. †Model is also adjusted for interactions
etween age and exposure to antiretroviral therapy. ‡p  0.05; §p  0.01. Adjusted estimates from generalized estimating equation models only.
LV  left ventricular; other abbreviations as in Table 1.
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December 28, 2010/January 4, 2011:76–85 Cardiac Status of HIV- and ART-Exposed Infantsonth and decreased over 6 months; in P2C2 HIV boys, it
ncreased over 6 months (Fig. 1A). The CHAART-1 girls
ere consistently about one-half an SD below the average of
he P2C2 HIV girls (Fig. 1B).
LV fractional shortening measurements for CHAART-1
oys changed from being above (but still below normal) at
month to approximately the same (and normal) at age 2
ears compared with P2C2 HIV boys (Fig. 1C). For girls,
he difference between the adjusted means of the 2 cohorts
as greatest at 1 month and remained statistically signifi-
ant at age 2 years (0.87 SD, p  0.001) (Table 2, Fig. 1D).
V end-diastolic dimension (Figs. 1E and 1F), end-systolic
imension (Figs. 1G and 1H), contractility (Figs. 1I and 1J),
nd end-diastolic septal wall thickness (Figs. 1K and 1L)
iffered by sex and ART treatment (Table 2).
LV end-diastolic posterior wall thickness (Fig. 2A), heart
ate (Fig. 2B), and weight-for-height (Fig. 2C) z-scores
iffered by cohort (Table 3). CHAART-1 infants consis-
ardiac and Anthropomorphic Outcomes Among 352 HIV-Negativey Exposure to Antiretr viral Therapy*†Table 3 Cardiac and Anthropomorphic Outcomes Among 352 Hby Exposure to Antiretroviral Therapy*†
Cardiac or Anthropomorphic Measure Study Birth 6
LV end-diastolic posterior wall thickness z-scores
CHAART-1 0.44 
P2C2 HIV 0.72 
 0.28
p value
Heart rate z-scores
CHAART-1 0.36
P2C2 HIV 0.17
 0.19
p value
Weight-for-height z-scores
CHAART-1 0.49
P2C2 HIV 0.41
 0.90
p value
LV end-systolic posterior wall thickness z-scores‡
CHAART-1 0.30
P2C2 HIV 1.06 
 0.76
p value
End-systolic septal wall thickness z-scores‡
CHAART-1 0.29 
P2C2 HIV 0.10
 0.39 
p value
LV afterload (end-systolic wall stress) z-scores‡
CHAART-1 0.15 
P2C2 HIV 0.68 
 0.53 
p value
Estimates from regression models are adjusted for age, sex, and race or ethnicity. †Sex-specific
ata from boys and girls are pooled. ‡Model is also adjusted for interactions between age and exp
quation models only.
Abbreviations as in Tables 1 and 2.ently had higher LV end-diastolic posterior wall thickness, tut their z-scores remained approximately one-half an SD
elow zero (p  0.01). Heart rate measures were 0.18 SD
igher in the CHAART-1 infants at all ages (p  0.002).
he heart rate z-scores in the CHAART-1 infants in-
reased from 0.36 SD at birth to 1.06 SD at 2 years (p 
.01). Weight-for-height z-scores were 0.79 SD higher in
he CHAART-1 infants than in the P2C2 HIV infants at 1
onth only (p  0.001), with the CHAART-1 measure-
ents above normal and the P2C2 HIV measurements
elow normal (p  0.01). Both cohorts improved to normal
fter 1 month.
LV end-systolic posterior wall thickness (Fig. 2D), end-
ystolic septal wall thickness (Fig. 2E), and LV afterload
Fig. 2F) showed a qualitative (crossing) interaction be-
ween age and exposure to ART (Table 3), resulting in
ignificant associations with ART only at certain ages. LV
nd-systolic posterior wall thickness measurements of both
ohorts were below normal at 1 month, with higher values for
ts Born to HIV-Positive Mothers,gative Infants B rn to HIV-Positive Mothers,
lation Mean Adjusted Estimate¶
1 Yr 2 Yrs Birth 6 Month 1 Yr 2 Yrs
0.54 0.43 0.52 0.38 0.60 0.40
0.80 0.54 0.70 0.57 0.78 0.58
0.26 0.10 0.18 0.18 0.18 0.18
0.02 0.02 0.02 0.02
1.22 1.00 0.36 1.02 1.13 1.06
0.92 0.94 0.17 0.83 0.95 0.88
0.30 0.06 0.18 0.18 0.18 0.18
0.002 0.002 0.002 0.002
0.09 0.05 0.39 0.28 0.14 0.01
0.16 0.17 0.40 0.08 0.17 0.14
0.07 0.23 0.79 0.20 0.03 0.13
0.001 0.39 0.88 0.52
0.37 0.13 0.33§ 0.30§ 0.34 0.13
0.16 0.18 1.03 0.19 0.15 0.22
0.21 0.05 0.70 0.49 0.19 0.09
0.001 0.01 0.25 0.64
0.05 0.33 0.33§ 0.04 0.08 0.35§
0.50 0.10 0.12 0.40 0.48 0.09
0.45 0.23 0.46 0.44 0.40 0.26
0.01 0.03 0.009 0.19
0.26 0.16 0.20 0.64 0.24 0.20
0.48 0.05 0.68 0.34§ 0.47 0.09
0.23 0.20 0.47 0.30 0.23 0.29
0.04 0.15 0.23 0.26
of exposure to antiretroviral therapy are not shown, because they were nonsignificant; therefore,
o antiretroviral therapy. §p  0.05; p  0.01. ¶Adjusted estimates from generalized estimatingInfanIV-Ne
Popu
Month
0.42
0.60
0.18
0.99
0.86
0.13
0.26
0.09
0.17
0.32
0.25
0.58
0.06
0.39
0.45
0.63
0.29
0.34
effects
osure the CHAART-1 cohort. Both cohorts improved to normal
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ystolic septal thickness z-scores from the CHAART-1 cohort
ere 0.40 SD lower than the P2C2 HIV measurements
uring the first year (p  0.05). Measurements from both
ohorts became approximately the same at age 2 years. LV
fterload showed the CHAART-1 cohort starting at 1 month
ith an average z-score 0.47 SD lower than the P2C2 HIV
easurements and ending approximately the same as the P2C2
IV measurements at 12 months and age 2 years.
iscussion
nfants of HIV-positive mothers exposed to ART showed
mproved LV contractility and fractional shortening during
he first 2 years of life compared to a non-ART-exposed
ohort of HIV-negative infants born to HIV-positive
others. However, ART exposure was also associated with
educed LV mass, septal thickness, and dimension, which
ere also below normal. In other settings, these 3 changes
an lead to progressive LV dysfunction (20–22). The
Figure 1 Cardiac Measurements of 136 CHAART-1 Infants and
Data from antiretroviral therapy (ART)–positive infants in the CHAART-1 study are s
HIV study are shown by the red line with solid boxes. Rectangles show interquart
resent outliers. EDD  end-diastolic dimension; ED SWT  end-diastolic septal wa
ventricular.ong-term cardiac effects of fetal exposure to ART are snclear. Our findings are consistent with the hypothesis that
ontrol of myocardial growth differs from control of myo-
ardial function and that ART exposure is associated with
ess myocardial growth but better myocardial function.
Higher LV contractility leads to a smaller LV end-
ystolic volume and a higher wall thickness and hence
owers LV wall stress at end-systole. A decrease in LV wall
tress reduces the stimulus to LV hypertrophy, and hence,
ower LV mass is the anticipated response to higher LV
ontractility.
Our ART-exposed cohort had better maternal health
han did the P2C2 HIV cohort and better infant LV
ontractility and fractional shortening. LV fractional short-
ning normalized in both groups by age 2 years, except for
HAART-1 girls, and LV contractility was better in the
HAART-1 group and remained normal or slightly above
ormal across all visits. Adding the significant maternal
ariables to the final multivariate models did not change the
RT exposure effects on echocardiographic parameters,
P2C2 HIV Infants
by the blue line with open boxes. Data from ART-negative infants in the P2C2
ges, and vertical lines show the 5th percentile to the 95th percentile. Dots rep-
ness; ESD  end-systolic dimension; FS  fractional shortening; LV  left216
hown
ile ran
ll thickuggesting that ART itself, not improved maternal health,
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December 28, 2010/January 4, 2011:76–85 Cardiac Status of HIV- and ART-Exposed Infantsffects LV function either directly or indirectly. We incor-
ectly speculated that improved maternal health resulted in
mproved LV contractility and fractional shortening (6).
As in rodents (23,24), ART exposure inhibited myocar-
ial growth, being associated with decreased septal thick-
ess and LV dimension and mass. These changes suggest an
verall loss of cardiac tissue with ART exposure, an inability
f the septum to grow in response to increasing body surface
rea, or both. Weight for height was not significantly
ifferent by ART exposure with follow-up, suggesting that
ody surface area–normalized z-scores for these variables
re appropriate.
Although our results suggest that ART is associated with
arly improved LV function, longitudinal changes in other
actors may lead to increasing mechanical stress, such as
ower LV mass, that may result in increased LV afterload,
hich could compromise long-term LV function, a finding
ound in anthracycline-treated childhood cancer survivors
20–22). Mechanistically, these changes could be induced
y apoptosis and by decreased hypertrophic signaling mech-
nisms related to ART growth-inhibiting effects, ART-
ssociated deoxyribonucleic acid mitochondrial mutations,
r gene polymorphism shifts (23–25), mechanisms similar
o that for pediatric cancer survivors with doxorubicin-
ssociated cardiomyopathy, a well-characterized example of
ate cardiotoxicity after early childhood drug exposure (26).
Perinatal myocardiocyte injury and death are significantly
elated to inflammation (27). Fetal inflammatory response
yndrome is associated with increased neonatal morbidity
Figure 2 Cardiac and Anthropomorphic Measurements of 136 C
Data from antiretroviral therapy (ART)–positive infant in the CHAART-1 study are sh
study are shown by the red line with solid boxes. Rectangles show interquartile r
sent outliers. BP  blood pressure; ED PWT  end-diastolic posterior wall thickne
thickness; Hgt  height; LV  left ventricular; Wgt  weight.28). Immune reconstitution inflammatory syndrome in dRT-exposed HIV-infected mothers may heighten inflam-
ation that contributes to myocardiocyte injury and re-
uced neonatal LV mass (29).
Exposure to ART was also associated with higher heart
ates, which have been associated with the rapid progression
f childhood HIV-associated disease (30). Sustained tachy-
ardia, as observed with ART exposure, may be cause or
ffect, but with secondary LV hypoplasia may explain our
V growth findings. Mild LV restrictive disease, with a
educed capacity for LV dilation and with a secondary
achycardia, is also possible. Reduced end-diastolic volume
s the initial limiting factor to cardiac output with secondary
ompensatory tachycardia is certainly the anticipated re-
ponse to detraining and to a restrictive cardiomyopathy, so
his sequence is also plausible. Alternatively, the decreased
V growth may be secondary to a direct ART effect, such as
itochondrial deoxyribonucleic acid damage from ART-
ssociated oxidative stress, resulting in LV hypoplasia that
ontributes to the observed increased LV contractility and
eart rate, especially in girls (23–25).
The effects of ART exposure on LV mass, dimension,
ractional shortening, and septal thickness were more pro-
ounced in girls. These differences might predict early and
dvanced cardiovascular disease in girls as they age. Our
ndings are similar to the effects of zidovudine effects in
ice, in which females were more sensitive to ART than
ales (31). Similarly, newborn girls have greater myocardial
njury marker elevations than newborn boys (27). Doxoru-
icin cardiotoxicity suggests an increased vulnerability of the
RT-1 Infants and 216 P2C2 HIV Infants
y the blue line with open boxes. Data from ART-negative infants in the P2C2 HIV
and vertical lines show the 5th percentile to the 95th percentile. Dots repre-
PWT  end-systolic posterior wall thickness; ES SWT  end-systolic septal wallHAA
own b
anges,
ss; ESeveloping female myocardium (20–22).
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Cardiac Status of HIV- and ART-Exposed Infants December 28, 2010/January 4, 2011:76–85The magnitude of the z-score differences in this study
ay appear to be small relative to those that guide the daily
linical decisions by cardiologists. However, their magni-
ude is consistent with findings in doxorubicin-treated
ediatric cancer survivors (20–22), who 20 to 30 years later
ave a 15-fold increase in the rate of heart failure compared
ith siblings and an 8.2-fold increase in cardiac mortality
ompared with U.S. population mortality data (32,33).
Zidovudine and its metabolites cross the placenta and are
ound in the fetal heart (34). The hypothesis that zidovu-
ine may be associated with cardiac mitochondrial dysfunc-
ion is supported by animal studies and by limited clinical
ata (35–39). Yet, zidovudine monotherapy showed no
ffect on the same LV structure and function measurements
n the present study in either HIV-negative or -positive
hildren (11,12). Follow-up studies of HIV-negative infants
orn to HIV-positive women have found neither detrimen-
al effects of perinatal zidovudine exposure nor clinically
mportant cardiovascular disease (8–10,12,40–42).
Combination ART (96% of CHAART-1 infants had
ombination therapy) has early and marked effects on LV
tructure and function. In rodents, combination ART pro-
uces more mitochondrial deoxyribonucleic acid mutations
han monotherapy (23–25,31). In contrast to nucleoside
everse transcriptase inhibitors, protease inhibitors in gen-
ral do not cross the placenta, suggesting that the effects
een likely result from nucleoside reverse transcriptase in-
ibitor combinations rather than protease inhibitors. Com-
ination ART compared with a nucleoside reverse tran-
criptase inhibitor alone in HIV-negative children was
ssociated with more lymphocyte abnormalities (43). Other
bnormalities in ART-exposed, HIV-negative children in-
lude anemia, neutropenia, thrombocytopenia, lower CD4
nd CD8 T-lymphocyte counts, and increased micronucle-
ted erythrocytes (43–45).
tudy limitations. The P2C2 HIV study (1991 to 1996)
nd the CHAART-1 study (2003 to 2006) were per-
ormed in different eras (before and after highly active
RT, respectively). This nonconcurrent design was used
or ethical reasons, because ART therapy could not be
ithheld from pregnant women. However, the cardiac
rotocol, clinical sites, study personnel, and the person
easuring echocardiograms were largely common to both
tudies.
As previously noted, a potential limitation of the use of
-scores is if the study population differs significantly from
he reference population in terms of anthropomorphic
easures. We found no evidence of such differences be-
ween our study population and the reference group.
HIV virulence might have increased in the decade be-
ween the studies, causing CHAART-1 measurements to
eviate more from normal than P2C2 HIV measurements.
owever, the CHAART-1 mothers had no evidence of
ore advanced disease.
1onclusions
etal exposure to ART is associated with reduced LV mass,
imension, and septal wall thickness and higher LV frac-
ional shortening and contractility during the first 2 years of
ife. We speculate that in utero exposure to ART may
mpair myocardial growth while initially improving LV
unction, although LV function was less than normal. These
ffects are more pronounced in girls. In the U.S., with more
han 100,000 HIV-negative infants exposed to ART, these
ndings clearly indicate a need for long-term monitoring of
hese infants to better define the mechanism of these effects
nd to evaluate their long-term clinical importance.
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